Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 6, 2021

Antengene to study selinexor in Phase II trial for myelofibrosis

China’s NMPA accepted the company’s application to conduct the trial of selinexor for myelofibrosis.

Antengene has plans to assess an Exportin 1 (XPO1) inhibitor, selinexor, in a Phase II clinical trial for the treatment of myelofibrosis (MF) patients in China.

China’s National Medical Products Administration (NMPA) has accepted the company’s investigational new drug (IND) application to conduct the trial.

Karyopharm Therapeutics discovered and developed selinexor, which is an oral selective inhibitor of nuclear export (SINE) compound and marketed as Xpovio in the US.

Under an exclusive development and marketing deal for some Asia-Pacific markets and the ASEAN countries, Antengene is presently developing the SINE compound.

The randomised, open-label, multi-centre Phase II trial will compare the safety and efficacy of selinexor to physician’s choice (PC) in MF subjects who received a minimum of six months of treatment with a Janus kinase 1/2 inhibitor.

It will enrol a total of about 112 subjects at 75 trial sites globally. Participants will be categorised in a 1:1 ratio to receive either selinexor or PC treatment.

Content from our partners
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide
Why Asia-Pacific is the next frontier for decentralized clinical trials

Antengene founder, chairman and CEO Dr Jay Mei said: “This acceptance by the NMPA of the IND application for the China study of selinexor in patients with MF marks another major step forward in our effort to develop selinexor into a novel cancer drug.

“It also paves the way for our ongoing exploration of additional indications for Antengene’s novel assets.”

MF is a clonal hematologic neoplasm that can occur as primary MF, polycythemia vera or essential thrombocythemia.

Currently, the company is carrying out five late-stage trials of selinexor to treat multiple myeloma, diffuse large B-cell lymphoma, non-small cell lung cancer and peripheral T and NK/T-cell lymphoma.

The SINE compound received priority review designation from the NMPA, as well as orphan drug status from the Ministry of Food and Drug Safety of South Korea.

Earlier this year, selinexor (Nexpovio) obtained conditional marketing authorisation from the European Commission to treat relapsed/refractory multiple myeloma in adults.

Antengene dosed the first subject in a Phase I/II HATCH trial of eltanexor (ATG-016) for treating patients with intermediate and higher-risk myelodysplastic syndrome in China in May 2021.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU